"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060890
|
| MeSH Number(s) |
D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
|
| Concept/Terms |
B7-H1 Antigen- B7-H1 Antigen
- Antigen, B7-H1
- B7 H1 Antigen
- Programmed Cell Death 1 Ligand 1
- B7-H1 Immune Costimulatory Protein
- B7 H1 Immune Costimulatory Protein
- PD-L1 Costimulatory Protein
- Costimulatory Protein, PD-L1
- PD L1 Costimulatory Protein
- Programmed Cell Death 1 Ligand 1 Protein
- CD274 Antigen
- Antigen, CD274
- Antigens, CD274
- CD274 Antigens
- B7H1 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".
This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2008 | 0 | 2 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 4 | 1 | 5 |
| 2014 | 5 | 1 | 6 |
| 2015 | 8 | 7 | 15 |
| 2016 | 12 | 10 | 22 |
| 2017 | 20 | 17 | 37 |
| 2018 | 29 | 18 | 47 |
| 2019 | 27 | 27 | 54 |
| 2020 | 33 | 32 | 65 |
| 2021 | 16 | 22 | 38 |
| 2022 | 13 | 38 | 51 |
| 2023 | 8 | 26 | 34 |
| 2024 | 10 | 14 | 24 |
To return to the timeline,
click here.
Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.
-
Nuclear PD-L1 compartmentalization suppresses tumorigenesis and overcomes immunocheckpoint therapy resistance in mice via histone macroH2A1. J Clin Invest. 2024 Nov 15; 134(22).
-
Tumour-intrinsic PDL1 signals regulate the Chk2 DNA damage response in cancer cells and mediate resistance to Chk1 inhibitors. Mol Cancer. 2024 Oct 30; 23(1):242.
-
Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies. Clin Cancer Res. 2024 Oct 15; 30(20):4768-4779.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Concordance of PD-L1 Expression in Metastatic Triple-negative Breast Cancer Between the 22C3 and E1L3N Antibodies Using Combined Positive Scoring. Appl Immunohistochem Mol Morphol. 2024 Oct 01; 32(9):417-424.
-
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity. Int Immunopharmacol. 2024 Dec 05; 142(Pt A):113004.
-
LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness. Nat Commun. 2024 Aug 27; 15(1):7366.
-
Cryo-Nanocatalyst Enhances Therapeutic Efficacy of Cryo-Immunotherapy through Necroptosis and Local Delivery of Programmed Death-Ligand 1 Inhibitors. ACS Nano. 2024 Sep 03; 18(35):24269-24282.
-
Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer. 2024 Dec 15; 155(12):2277-2286.
-
SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. Oncoimmunology. 2024; 13(1):2376264.